Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Zollinger-Ellison Syndrome 1Thyroid Cancer, Papillary 1Somatostatinoma 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Salts 1Panobinostat 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glucagonoma × pazopanib × Endocrine × Clear all
NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡